But a challenge to an Orange Book patent, should a brand-name manufacturer decide to fight in court, also delays a generic’s approval for 30 months. The FTC says that drugmakers needlessly list ...
After the FTC’s November action, several manufacturers de-listed patents and three top drugmakers announced they would cap inhaler out-of-pocket costs at $35. “By filing bogus patent listings, pharma ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
And they don't really have the inside view of what's happening at the FDA.” Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, ...
But other companies argue that the FTC’s accusation that their patents are junk isn’t accurate. McGrevy: So, what’s next? Gabriel: If drug manufacturers don’t remove their junk patent listings, ...
the FTC highlighted specifically its disputes of so-called “junk patent listings” for “blockbuster” weight loss medications. To date, the FTC’s Orange Book patent disputes have been ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, and those can be pretty expensive. But the FTC hasn’t announced if ...